首页 | 本学科首页   官方微博 | 高级检索  
     

新旧《药品不良反应报告和监测管理办法》对比分析
引用本文:侯永芳,王丹,田春华,王玲,杜晓曦. 新旧《药品不良反应报告和监测管理办法》对比分析[J]. 中国药事, 2011, 25(11): 1075-1078,1088
作者姓名:侯永芳  王丹  田春华  王玲  杜晓曦
作者单位:国家食品药品监督管理局药品评价中心,北京,100045
摘    要:目的探讨新《药品不良反应报告和监测管理办法》的先进性。方法从监管部门职责、不良反应报告和监测过程各个环节,对比分析《药品不良反应报告和监测管理办法》修订前后的差异,阐述其实施的重要意义。结果与原法规比较,新法规明确了省以下监管部门和监测机构的职责,细化、规范了不良反应报告要求,完善、强化了评价与控制措施,引入重点监测,使不良反应被动监测变为主动、被动相结合。结论新法规为及时、全面获取药品不良反应相关信息、科学评价药品安全性问题、有效控制药品风险提供了有力保障。

关 键 词:药品不良反应  报告  管理办法  对比

A Comparative Analysis Between the New Version of Measures for the Reporting and Monitoring of Adverse Drug Reactions and the Original One
Hou Yongfang,Wang Dan,Tian Chunhua,Wang Ling,Du Xiaoxi. A Comparative Analysis Between the New Version of Measures for the Reporting and Monitoring of Adverse Drug Reactions and the Original One[J]. Chinese Pharmaceutical Affairs, 2011, 25(11): 1075-1078,1088
Authors:Hou Yongfang  Wang Dan  Tian Chunhua  Wang Ling  Du Xiaoxi
Affiliation:Hou Yongfang,Wang Dan,Tian Chunhua,Wang Ling and Du Xiaoxi*(Center for Drug Reevaluation,SFDA,Beijing 100045)
Abstract:Objective To probe into advancement of new Measures for the Reporting and Monitoring of Adverse Drug Reactions(hereinafter referred to as Measures).Methods To compare and analyze differences between two versions of Measures,referring to the responsibilities of regulatory authorities and supervisory agencies and all aspects of the reporting and monitoring progress of adverse drug reaction,elaborating the significance of the new Measures implementing.Results comparing with the original Measures,the new one cl...
Keywords:adverse drug reactions  reporting  measures  comparison  
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号